Evidence Based This post has 14 references
4.3 /5
3

Erythropoietin & Erythropoiesis-Stimulating Agents: Uses + Risks

Written by Mathew Eng, PharmD | Last updated:
Puya Yazdi
Medically reviewed by
Puya Yazdi, MD | Written by Mathew Eng, PharmD | Last updated:

SelfHacked has the strictest sourcing guidelines in the health industry and we almost exclusively link to medically peer-reviewed studies, usually on PubMed. We believe that the most accurate information is found directly in the scientific source.

We are dedicated to providing the most scientifically valid, unbiased, and comprehensive information on any given topic.

Our team comprises of trained MDs, PhDs, pharmacists, qualified scientists, and certified health and wellness specialists.

All of our content is written by scientists and people with a strong science background.

Our science team is put through the strictest vetting process in the health industry and we often reject applicants who have written articles for many of the largest health websites that are deemed trustworthy. Our science team must pass long technical science tests, difficult logical reasoning and reading comprehension tests. They are continually monitored by our internal peer-review process and if we see anyone making material science errors, we don't let them write for us again.

Our goal is to not have a single piece of inaccurate information on this website. If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please leave a comment or contact us at [email protected]

Note that each number in parentheses [1, 2, 3, etc.] is a clickable link to peer-reviewed scientific studies. A plus sign next to the number “[1+, 2+, etc...]” means that the information is found within the full scientific study rather than the abstract.

Erythropoietin

Erythropoietin (EPO) is a hormone that stimulates the production of new red blood cells. Drug forms of EPO are used in anemia to reduce the need for blood infusions. EPO is also popular as a performance-enhancing substance and is banned in professional sports. Learn about all the uses and health risks of EPO.

What is Erythropoietin?

Erythropoietin (also known as EPO, hematopoietin, or hemopoietin) is a hormone that stimulates the production of red blood cells, also called erythropoiesis. The primary role of red blood cells is to carry oxygen throughout the body [1].

The body naturally maintains a low level of EPO to ensure there is a constant level of red blood cells. When oxygen levels are low (hypoxia), the body will significantly increase the production of EPO, up to 1,000 fold [1].

In adults, EPO is primarily produced in the kidneys. In newborns and the developing fetus, EPO is primarily produced in the liver [1].

card-7652883-back

Erythropoiesis-Stimulating Agents (ESA)

Synthetic forms of EPO are available and are referred to as erythropoiesis-stimulating agents (ESA). These ESAs are FDA-approved for the treatment of several different types of anemia and also to reduce the need for blood transfusions during surgery [2].

In the United States, there are two kinds of ESA available:

  • Epoetin alfa (Procrit, Epogen)
  • Darbepoetin alfa (Aranesp)

These ESA medications work similar to the body’s own erythropoietin, they stimulate the production of new red blood cells [3].

However, ESA drugs also carry several significant safety warnings as they can increase the risk of blood clots and cancer growth, potentially leading to death [3].

Misuse of EPO

EPO has a long history of misuse in competitive sports. In particular, endurance sports such as cycling and long-distance running have been the subject of a number of doping cases with ESAs [4].

In these sports, the misuse of ESAs can provide a competitive advantage by increasing the number of red blood cells in the blood, which can potentially improve oxygen delivery and endurance [4].

The use of EPO and ESAs in professional sports is prohibited by the World Anti-Doping Agency [5].

Uses of ESA

Below we’ll discuss the FDA-approved uses of ESA medications.

ESAs should always be taken under the direction of a doctor. The improper use of ESAs can increase the risk of heart attacks, strokes, cancer, and even death.

1) Anemia

Anemia is a condition where the blood doesn’t contain enough healthy red blood cells, which can leave those with anemia feeling tired and weak. There are many possible causes of anemia, such as blood loss, iron deficiency, and malaria, to name a few [6].

ESAs are FDA-approved for the treatment of several different types of anemia, including anemia caused by [2]:

  • Chronic kidney disease
  • Treatment of HIV
  • Chemotherapy

In these types of anemia, regular blood transfusions are sometimes necessary to maintain a proper level of red blood cells.

A number of large clinical trials have demonstrated that ESAs can increase hemoglobin levels in these types of anemia and decrease the need for blood transfusions. According to some research, more than 95% of patients no longer require transfusions after 3 months of treatment with ESAs [2, 7].

However, the negative effects of ESA can severely limit its use for anemias. We’ll detail these limitations further on.

2) Surgery

ESAs can be used for certain types of surgery to reduce the need for red blood cell transfusions. More specifically, ESAs are only appropriate for patients who are at a high risk for blood loss and are undergoing elective, noncardiac, nonvascular surgery [2].

According to multiple clinical trials, ESAs can decrease the need for blood transfusions for this type of surgery [2, 8].

Research on ESA

Clinical Research

The following purported benefits of ESAs are only supported by limited, low-quality clinical studies. There is insufficient evidence to support the use of ESAs for any of the uses listed below. This medication should always be taken under the guidance of a doctor.

Protecting Against Brain Injury

There is some evidence that ESAs may have protective effects in the brain, especially in newborns.

For example, a study of 200 low birth weight infants found that ESAs may protect the brain against injury from intraventricular hemorrhage, a type of bleeding in the brain. In the study, infants who received ESAs went to perform better on intelligence tests as children compared to those who did not receive treatment [9].

Another prospective case-control study of 45 newborns found that ESAs may also protect against hypoxic-ischemic encephalopathy, a type of brain injury caused by oxygen deprivation. The study found that infants who received ESAs had fewer neurologic and developmental disabilities [10].

Wound Healing

Oral mucositis is a condition characterized by painful swelling and ulcers in the mouth. A randomized placebo-controlled trial of 80 patients with oral mucositis caused by chemotherapy found that an EPO mouthwash may reduce the duration and incidence of this condition [11].

According to a different study of 12 patients who had a gingival graft, an EPO topical gel may reduce inflammation and speed up healing time after a gingival graft procedure [12].

Animal Research

No clinical evidence supports the use of ESAs for any of the conditions listed in this section. Below is a summary of the existing animal-based research, which should guide further investigational efforts. However, the studies listed below should not be interpreted as supportive of any health benefit.

Protecting Against Eye Damage

A study in mice found that ESAs may reduce cell death and oxidative stress after an eye injury. However, the researchers also found that ESAs may actually increase cell death and oxidative stress when used prior to eye trauma or immediately after [13].

Bone Regeneration

According to a goat study, ESA treatment may increase bone formation and angiogenesis, the formation of new blood vessels [14].

Safety of ESAs

Clinical research shows that the use of ESAs can pose a significant health risk in certain individuals. This is not a comprehensive list of risks and the use of ESAs depends on a number of factors. A doctor will have to weigh the benefits and risks to determine if ESA treatment is appropriate.

Warnings

Risk in Chronic Kidney Disease

For those with chronic kidney disease, ESAs can increase the risk of stroke, heart attack, and death when hemoglobin levels are greater than 11 g/dL [2].

Blood levels of hemoglobin should be monitored to ensure hemoglobin levels do not become too high [2].

Cancer Risk

There is evidence that ESAs can increase the risk of tumor progression or recurrence in patients with breast, lung, head and neck, lymphoid, and cervical cancers. ESAs have been shown to shorten overall survival in these types of cancer as well [2].

Surgery Risk

ESAs can increase the risk of deep venous thrombosis (DVT), a type of blood clot that typically occurs in the leg or thigh. Those taking ESAs and undergoing surgery should receive proper treatment to reduce the risk of DVTs [2].

About the Author

Mathew Eng

Mathew Eng

PharmD
Mathew received his PharmD from the University of Hawaii and an undergraduate degree in Biology from the University of Washington.
Mathew is a licensed pharmacist with clinical experience in oncology, infectious disease, and diabetes management. He has a passion for personalized patient care and believes that education is essential to living a healthy life. His goal is to motivate individuals to find ways to manage their chronic conditions.

Click here to subscribe

RATE THIS ARTICLE

1 Star2 Stars3 Stars4 Stars5 Stars
(23 votes, average: 4.26 out of 5)
Loading...

FDA Compliance

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.